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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
• To evaluate the effects of cognitive training on cognitive and non-cognitive outcomes for people with mild to moderate
dementia and their caregivers.
• To compare the effects of cognitive training with those of other non-pharmacological interventions, including cognitive
stimulation or rehabilitation.
• To identify and explore factors related to intervention and trial design that may be associated with the efficacy of cognitive
training.
B A C K G R O U N D
Description of the condition
Dementia is a clinical syndrome in which functional indepen-
dence is compromised due to intellectual and cognitive impair-
ment (mostly of gradual onset). It is typically caused by age-related
pathophysiological processes. Alzheimer’s disease (AD) and mixed
AD and cerebrovascular disease are the most common causes of
dementia in older people (Alzheimer’s Association 2018). Other
common causes include Lewy-body pathology (in dementia with
Lewy bodies (DLB) and Parkinson’s disease dementia (PDD))
and frontotemporal lobar degeneration (in the frontotemporal
dementias (FTD), and there are numerous other, rarer causes)
(Alzheimer’s Disease International 2009).
Dementia due to most neurodegenerative conditions is usu-
ally associated with aggregates of folded or misfolded proteins
(Villemagne 2018). In the case of dementia due to AD, this in-
cludes aggregates of the Aβ protein that form into plaques in
the space between neurons, as well as aggregates of misfolded tau
protein that form neurofibrillary tangles inside neurons. Other
protein-aggregates are implicated in other neurodegenerative dis-
ease (e.g. TDP-43 in FTD, alpha-synuclein protein aggregates in
dementia with Lewy bodies). Aggregated proteinopathies usually
spread in a predictable and well-described manner through corti-
cal and subcortical regions (Braak & Braak 2012). In the case of
most dementia aetiologies, the pathophysiological chain of events
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commences years or even decades before the onset of obvious clin-
ical symptoms, at which stage individuals are increasingly brought
to clinical attention (Alzheimer’s Association 2018).
Regardless of cause, dementia usually has an insidious onset and
progressive course (although in some cases, e.g. vascular cogni-
tive impairment, a more rapid onset may be seen) (Wilson 2012).
While the clinical presentation in the early or mild stages may
vary according to the underlying disease aetiology, global cognitive
impairment, changes in personality and behaviour, and compro-
mised functional independence are common characteristics with
clinical progression. Cognitive impairment (in the case of AD and
vascular disease) and behavioural, personality, or language changes
(in the case of frontotemporal neurodegeneration) are typically
present well before a clinical diagnosis is made, but in the early
stages these can be difficult to differentiate from common age-re-
lated changes or from symptoms associated with common psychi-
atric conditions (e.g. depression), a factor that often leads to delays
in bringing the situation to medical attention. During the pre-de-
mentia phase, individuals usually present with mild cognitive im-
pairment (Albert 2011; Petersen 2004), a period in which cogni-
tive impairment can be detected on formal examination, but there
is usually no, or only minimal, impairment in the ability of the
individual to carry out most activities of daily living. In the mild
to moderate stages of dementia, cognitive impairment becomes
more profound and widespread, functional disability becomes in-
creasingly evident - particularly in relation to more complex activ-
ities - and caregiver burden tends to significantly increase (Berger
2005; Gaugler 2000). In the more advanced stages of dementia,
most cognitive and functional abilities are profoundly impaired,
and behavioural changes such as apathy, depression, aggression
and agitation are frequently observed (Förstl 1999).
Despite some overlap, the cognitive symptom signature that char-
acterises the different disease aetiologies that tend to develop into
dementia can often be distinguished, at least in the early stages.
In the case of dementia due to AD, the earliest cognitive signs on
formal neuropsychological examination are almost invariably re-
lated to episodic memory function. Within the memory domain,
the most striking deficits are usually observed on measures of new
learning and delayed recall, deficits which precede the diagnosis of
AD by several years (Weintraub 2012). Once deficits on measures
of learning and memory have developed, individuals often show
increasing difficulty performing tasks related to semantic mem-
ory, language, executive functions, and visuospatial/constructional
abilities. In dementia with Lewy bodies, early cognitive impair-
ments are more likely to involve striking visuospatial deficits, fluc-
tuating attention and reduced working memory capacity, and the
development of vivid hallucinations. In dementias related to fron-
totemporal lobar degeneration, early symptoms may be predomi-
nantly behavioural and related to social cognition in behavioural-
variant FTD, or involve predominantly language skills and verbal
expression in the temporal subtypes (Weintraub 2012). Although
impaired performance on measures of episodic memory is also
central to vascular dementia, people with this condition typically
display a more striking deficit on executive and attention tasks, as
well as on measures of semantic knowledge and visuospatial func-
tion (Graham 2004).
Dementia is highly prevalent in older people, is a leading cause
of disability worldwide, and is associated with enormous finan-
cial, emotional, and societal burden (Wimo 2017), making re-
search in this area a global priority (World Health Organization
2012). Despite years of research and numerous clinical trials, no
cure is yet available for any of the irreversible causes of demen-
tia. Cholinesterase inhibitors remain the primary pharmacological
treatment for the cognitive symptoms in AD and related demen-
tias; however, the effects of these drugs are not universal and are
always temporary (Birks 2006). A range of non-pharmacological
interventions (NPIs) that target different aspects of the clinical
syndrome, associated disability and caregiver burden are available
(for a comprehensive systematic review, see Olazaran 2010). NPIs
are generally not disease-specific and do not directly engage un-
derlying biological targets, and are therefore not ’disease-modify-
ing’. On the other hand, NPIs are more likely to target a broader
spectrum of clinically meaningful outcomes, and are less likely to
cause adverse reactions. Within the broad category of NPIs, cogni-
tion-oriented treatments, and particularly cognitive training, have
been the subject of much interest among researchers, clinicians,
and the general public.
Description of the intervention
“Cognition-oriented treatments” (COTs), referred to previously
as “cognition-focused interventions” (Clare 2002; Clare 2004), is
an umbrella term referring to a group of NPIs in which a range
of techniques are applied in order to engage thinking and cogni-
tion with various degrees of breadth and specificity. Unlike NPIs
that are primarily oriented toward outcomeswhich are behavioural
(e.g. wandering), emotional (e.g. anxiety) or physical (e.g. seden-
tary lifestyle), in COTs the goals include improving or maintain-
ing cognitive processes or addressing the impact of impairment
in cognitive processes on associated functional ability in daily life
(Bahar-Fuchs 2013; Clare 2004). Cognitive training (CT), some-
times described in the literature as ’brain training’, ’retraining’ or
’remediation’) typically involves guided practice of a set of struc-
tured - and usually standardised - tasks, designed to train rela-
tively well-defined cognitive processes and abilities such as speed
of information processing, attention, memory, or problem-solving
(Bahar-Fuchs 2013; Mowszowski 2010). Other COTs described
in the literature include cognitive stimulation therapy (CST), and
cognitive rehabilitation (CR), and these approaches are regarded
as distinct in terms of their underlying theoretical assumptions,
core elements, and the contexts or populations in which they have
been traditionally applied, but it is acknowledged that some over-
lap exists and that differentiating between these approaches is not
always straightforward (Bahar-Fuchs 2013; Gates 2014). Indeed,
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these terms have been and continue to be applied somewhat inter-
changeably in the literature (e.g. Fernandez-Prado 2012;Giordano
2010), despite the availability of broad definitions and descrip-
tions of these distinct forms of intervention (Bahar-Fuchs 2013;
Clare 2004; Woods 2012). Table 1, below, summarises key defin-
ing features and common properties of these approaches. Cog-
nitive stimulation is the focus of a separate Cochrane Review,
which concluded that general cognitive stimulation consistently
produces improvements in general cognition and, in some cases,
in self-reported quality of life and well-being, primarily for peo-
ple with mild to moderate dementia (Woods 2012). Cognitive re-
habilitation, which is an inherently individualised approach em-
phasising collaborative goal-setting and a functional orientation
(Bahar-Fuchs 2016; Clare 2001), has been considered alongside
CT in previous versions of this Cochrane Review (Bahar-Fuchs
2013; Clare 2004); however, as the body of evidence for this ap-
proach has increased in recent years, and as it involves different
methods and targets different outcomes, it will be considered in a
separate Cochrane Review and the current review will accordingly
focus only on CT.
Cognitive training
Cognitive training is historically couched within the broader field
of neuropsychological rehabilitation of individuals with brain in-
jury and neurological diseases, with efforts to systematically re-
train specific cognitive functions originally described by clini-
cal researchers such as Leonard Diller and Yehuda Ben-Yishay in
their pioneering work with victims of stroke and head trauma
throughout the 1970s (Ben-Yishay 1978; Diller 1974). In the
early 1980s, the principles of CT began to be applied in cogni-
tively healthy older adults with subjective cognitive complaints
(e.g. Zarit, 1981), however it was not until the late 1980s that
cognitive training was first attempted with people with demen-
tia (e.g. Beck 1988). A central assumption underlying cognitive
training is that practice has the potential to improve or at least
maintain functioning in the given cognitive domain. A further
important assumption is that any effects of practice will generalise
beyond the immediate training context. In other words, improved
performance on a given task should lead to improved performance
on other, related tasks that depend on the same cognitive process
or ability. Although this last assumption has not often been sup-
ported by the evidence (Owen 2010; Papp 2009), some have ar-
gued that failure to produce transferable benefits is related in part
to problems with task design (Jaeggi 2010). As noted above, CT
traditionally involves the repeated practice of a set of structured
tasks designed to target particular cognitive processes and abili-
ties. Some authors have proposed that cognitive training should be
divided into subtypes of cognitive exercise, and strategy training
(Gates 2011), which involves instruction and practice in the use
of specific cognitive strategies designed to further enhance perfor-
mance, orminimise the impact of impaired cognition (e.g.method
of loci, visual imagery) (Hampstead 2016). Cognitive training is
different to the type of skill training often exercised by occupa-
tional therapists in that the target is usually an underlying pro-
cess or ability, rather than a specific skill. While early versions of
CT tended to be delivered in an inflexible ’one size fits all’ ap-
proach, technological developments are leading to increasing tai-
loring of training focus based on individual cognitive profile and
adaptive difficulty level in recent years (Bahar-Fuchs 2017; Peretz
2011). Cognitive training may be offered through individual ses-
sions (Davis 2001; de Vreese 1998a; de Vreese 1998b Farina 2002;
Koltai 2001; Loewenstein 2004), or group sessions (Cahn-Weiner
2003; Ermini Fuenfsch 1995; Kesslak 1997; Koltai 2001; Moore
2001), or may be facilitated by family members with therapist
support (Neely 2009; Quayhagen 1995a; Quayhagen 2000). Ini-
tially delivered mainly in paper-and-pencil formats, computerised
cognitive training (CCT) programmes have largely replaced more
traditional methods over the past two decades (Davis 2001; de
Vreese 1998; Quayhagen 1995; Quayhagen 2000). In some cases,
the tasks or activities which form the focus of practice/training
are analogues of actual daily activities, such as doing online shop-
ping or setting up a dinner table (Farina 2002; Loewenstein 2004;
Neely 2009; Zanetti 1994; Zanetti 1997; Zanetti 2001), and in
these cases the distinction between cognitive training and func-
tional skills training becomes more difficult. Skills-oriented inter-
ventions inwhich the target task is well structured, broken into rel-
atively well-defined underlying cognitive performance elements,
and where the outcomes of interest are cognitive processes rather
than merely the performance of the intervention task itself (e.g.
Neely 2009), appear to fit the conceptual framework of cognitive
training. Conversely, where the focus of the intervention is a spe-
cific skill and there is no expectation to improve an underlying
cognitive ability/process, and where the cognitive underpinnings
are unclear or only vaguely addressed, the intervention might be
best classified as ‘functional skills training’. In accordance with the
suggestion that cognitive training may enhance the effects of phar-
macological therapy (Newhouse 1997), some studies have evalu-
ated the efficacy of cognitive training in combination with the use
of cholinesterase-inhibitors (Cahn-Weiner 2003;de Vreese 1998a;
de Vreese 1998b Loewenstein 2004), or other medications (Heiss
1993; Yesavage 1981).
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Table 1. Selected characteristics of cognitive training, stimulation, and rehabilitation
Cognitive training Cognitive rehabilitation Cognitive stimulation
Target Impairment Participation restriction Participation restriction
Context Structured tasks and environ-
ments
In the person’s natural environ-
ment
Usually in a clinic/residential
care, or daycare setting
Focus of intervention Specific cognitive abilities and
processes. Psychoeducation and
strategy training sometimes in-
cluded
Groups of cognitive abilities
and processes required to per-
form individually-relevant ev-
eryday tasks. Behaviour, envi-
ronment and everyday activity.
Psychoeducation and strategy
training sometimes included
Orientation, Global cognitive
status
Format Individualised or group Individualised Typically group
Proposed mechanism of ac-
tion
Mainly restorative;mechanisms
related to neuroplasticity
A combination of restorative
and compensatory approaches;
reduction of ’excess disability’
Improved orientation, general
activation
Goals Improved or maintained ability
in specific cognitive domains
Performance and functioning
in relation to collaboratively set
behavioural or functional goals
Improve overall orientation and
engagement in pleasant abilities
How the intervention might work
Cognitive training aims to improve or maintain specific cognitive
processes or global cognitive ability, and when used as an inter-
vention approach with clinical populations, there is also an expec-
tation that improvements in cognition will generalise to improve-
ments in functional outcomes. Much has been written about the
lack of unifying theories in the field of NPIs, including in rela-
tion to interventions aimed at changing behaviour (Michie 2008),
cognition and function (Wilson 2002), and in relation to reha-
bilitation in general (Hart 2014). Indeed, no single theory exists
that comprehensively explains such issues as why or how cognitive
training should lead to improved cognitive and functional out-
comes, whether and why some cognitive domains are more likely
to respond to training than others, whether training should target
single or multiple cognitive domains, or whether it should focus
on improving impaired functions or building on preserved ones.
To various extents, cognitive training interventions in healthy and
in clinical populations draw instead on a range of theories and
discoveries grounded in cognitive neuroscience (e.g. Jaeggi 2008;
Sohlberg 1987), clinical practice and rehabilitation of patientswith
neurological injuries and diseases (Stuss 1999; Ponsford 2012),
and continues to be shaped in response to relevant technological
developments including in the gaming industry (Anguera 2015).
Unfortunately, many cognitive training interventions have been
and continue to be developed without clear reference to any rele-
vant theoretical work.
A central assumption held bymany advocates of cognitive training
is that training an underlying cognitive ability or process will lead
to generalised improvements that go beyond the training context
(Lampit 2014). In cognitively healthy younger and older adults,
and to a lesser extent, in individuals with mild cognitive impair-
ment (MCI), there is little doubt that CT leads to improvements
on trained or ’criterion’ tasks. However, in both healthy and clini-
cal populations, the evidence concerning learning transfer remains
mixed, and the issue is hotly debated, with much of the debate
concerning the identification of barriers and enablers of transfer
of gains to untrained tasks that reflect the cognitive domain tar-
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geted by the training (near transfer) and other untrained cognitive
domains as well as non-cognitive outcomes (far transfer) (Jaeggi
2010). In a recent comprehensive review and critique of the com-
mercial cognitive training industry, Simons and colleagues point
out that the discussion concerning transfer of learning can be
traced back to very early theoretical accounts (Simons 2016), such
as the so-called formal discipline theory, and the theory of transfer
by identical elements proposed by Edward Thorndike in the early
20th century. It is beyond the scope of this review to cover these in
detail, but a critical discussion of these accounts in relation to the
cognitive training literature and industry is included in the review
by Simons and colleagues (Simons 2016). Contemporary empir-
ical findings suggest that factors that appear to be implicated in
cognitive training-related gain-transfer include the degree of sim-
ilarity or overlap in elements of trained and transfer tasks, extent
of actual gain on trained tasks, baseline cognitive abilities, and age
(Zinke 2014).
In addition to theories of learning and transfer, knowledge and ex-
pertise related to brain-behaviour relationships - as well as ofmech-
anisms of injury, disease and recovery - are critical in informing the
development of COTs, including cognitive training, in the context
ofworkwith personswith acquired disorders of the central nervous
system (including traumatic brain injury, stroke and neurodegen-
erative conditions). Historically, such interventions have reflected
twobroad conceptual frameworks for the recovery of function after
brain illness or injury: a restorative approach, and a contextualised
or compensatory approach (Ylvisaker 2002). Techniques usually
associated with cognitive rehabilitation, such as optimising resid-
ual cognitive abilities in impaired domains andmaking themost of
unimpaired cognitive abilities, lend themselves more to compen-
satory approaches (Clare 2001b). In contrast, techniques usually
associated with CT, such as the repeated exercise of standardised
cognitive tests of increasing difficulty, and the targeting of specific
cognitive domains, tend to reflect restorative principles and “thrive
on the lure of neuroplasticity” (Rabipour & Raz 2012). Indeed,
a range of neuroplasticity-related observations in animal and hu-
man studies, including changes at the molecular, synaptic, struc-
tural, and functional level associated with enriched environments
and a structured training programme, are routinely cited as the
proposed mechanisms of action in cognitive training (Valenzuela
2012). In recent years, growing evidence has shown that cognitive
training is associated with changes in patterns of neural activation
in key brain regions in healthy older adults (Belleville 2014), and
in people with MCI (Belleville 2011; Hampstead 2011). Such in-
creased brain activation may be the result of processes of synaptic
growth and repair triggered by repeated practice on standardised
tests.
Why it is important to do this review
The Alzheimer’s disease drug development pipeline is slow and
trials of disease modifying treatments have generally failed to pro-
duce improvements in any clinically-meaningful outcomes, de-
spite succeeding in disrupting targeted pathophysiological pro-
cesses (Cummings 2014; Cummings 2016; Salomone 2012), lead-
ing some to question the relevance of the dominant amyloid cas-
cade hypothesis when it comes to the development of an effective
treatment for dementia as a clinical syndrome (D’Alton 2011).
NPIs aimed at developing ways for living better with dementia, in
part by targeting relevant clinical outcomes and caregiver burden,
are assuming an increasingly central role in the management of
dementia and are recognised as an important adjunct, and even al-
ternative, to available pharmacological treatments. A recent Lancet
Commission on Dementia Prevention, Intervention, and Care ar-
gues that some NPIs can already play an important role in manag-
ing some of the cognitive, behavioural and neuropsychiatric symp-
toms of dementia, and points to the positive findings for cognitive
stimulation therapy and the preliminary supportive evidence on
cognitive rehabilitation (Livingston 2017).
In healthy older adults (Edwards 2017; Lampit 2014), and in per-
sons with MCI (Chandler 2016; Hill 2017), systematic review
findings on the effects of cognitive training on cognitive and sev-
eral non-cognitive outcomes have been generally encouraging, and
factors associated with increased intervention efficacy in CT are
becoming better understood. Indeed, in recently published clinical
practice guidelines for MCI, cognitive training has been classified
as having Level C evidence, meaning that clinicians may recom-
mend this form of intervention (Petersen 2018).
In contrast, most systematic reviews of CT for persons with
dementia have to date produced largely negative findings (e.g.
Bahar-Fuchs 2013; Hill 2017; but see Sitzer 2006). Our previous
Cochrane Review of CT for persons with dementia included 11
randomised controlled trials, but there was no evidence to sup-
port CT in relation to any of the examined outcomes. We noted,
however, that the certainty of these findings may be reduced by
the relatively small number of highly heterogenous studies, which
were often of low methodological quality. Against the background
of a heavily divided scientific community, and an ever growing in-
dustry of commercial CT products that have at times made highly
misleading claims, it is vital that clinicians, policy-makers, and the
general public are presented with up-to-date, rigorous and unbi-
ased review of the current literature on cognitive training for per-
sons with mild to moderate dementia.
O B J E C T I V E S
• To evaluate the effects of cognitive training on cognitive
and non-cognitive outcomes for people with mild to moderate
dementia and their caregivers.
• To compare the effects of cognitive training with those of
other non-pharmacological interventions, including cognitive
stimulation or rehabilitation.
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• To identify and explore factors related to intervention and
trial design that may be associated with the efficacy of cognitive
training.
M E T H O D S
Criteria for considering studies for this review
Types of studies
In keeping with previous version of this review, and to ensure the
inclusion of unbiased estimates of treatment effects only (Reeves
2011), we will only consider randomised controlled trials (RCTs)
for inclusion. Wherever possible, we will not exclude studies pub-
lished in a language other than English, and we will make every
effort to obtain an English translation from the authors. In cases
where a translation cannot be obtained from the authors, we will
engage in reasonable efforts to obtain a reliable translation, and
will only exclude a study if these efforts are unsuccessful.
Types of participants
We will include participants with a medical diagnosis of all-cause
dementia or of any specified subtype of dementia as long as the
underlying aetiology was assumed to be non-reversible. The di-
agnosis of dementia should be made on the basis of established
clinical or research diagnostic criteria, including criteria specified
by the following.
• The Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition (DSM-V, APA 2013) or earlier versions (APA
1995)
• The International Classification of Diseases, Tenth Revision
(ICD-10) (WHO 1992)
• The National Institute of Neurological and
Communicative Disorders Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA) (McKhann 1984)
• The National Institute of Health-Alzheimer’s Association
(NIA-AA) (McKhann 2011)
• The Association Internationale pour la Recherché et
l’Enseignement en Neurosciences (NINDS-AIREN) (Roman
1993).
• Vascular Impairment of Cognition Classification Consensus
Study (McKeith 1996; McKeith 2006; McKeith 2017)
• The International Behavioural Variant FTD Criteria
Consortium (FTDC) (Skrobot 2017)
On average, participants in included studies will be classified as
being in the mild to moderate level of severity. Dementia severity
will usually be determined in primary trials on the basis of group
mean scores, ranges of scores or individual scores on a standardised
scale such as scores of over 12 at the Mini-Mental State Examina-
tion (MMSE; Folstein 1975) or scores of 0.5 to 2 on the Clinical
Dementia Rating (CDR 2; Hughes 1982).
• Studies in which it is clear that only small proportion of
participants (i.e. fewer than 15%) falls within the more severe
range or the questionable dementia range will be considered
acceptable if this information is clearly indicated in the study.
• Qualifying participants will generally be residing at home,
or in a residential care facility. We will exclude studies in which
recruited participants could be long-term residents of psychiatric
hospitals, where pre-existing psychiatric conditions are likely to
be present.
• We will set no specific age restrictions, although it is
expected that, with the exception of participants with younger
onset dementia (YOD), most participants will be 65 years of age
and older.
• No restrictions will be placed on current pharmacological
treatment. Where available, information about participants’ use
of cholinesterase inhibitors will be noted.
• Primary studies which include a mixture of participants,
only some of whom meet our inclusion criteria (e.g. dementia
and MCI), are eligible for inclusion as long as outcomes are
reported separately for the group of interest.
Types of interventions
Experimental interventions
Interventions meeting our definition of cognitive training (CT)
are eligible for inclusion. As the terms used to refer to CT vary
considerably, interventions may be referred to as ’brain’ or ’mental’
training and theymay be described as ’retraining’, ’exercise’, ’stimu-
lation’, ’rehabilitation’, ’therapy’, ’remediation’, ’support’, etc. Our
operational definition of eligible interventions includes the fol-
lowing criteria.
• Participants are trained on tasks designed to target one or
more cognitive processes either directly or indirectly. Training
generally takes the form of repeated practice. Trials in which the
primary goal was to compare performances of participants who
learned how to perform a task under different learning
conditions (e.g. errorless versus errorful) in a single session
(single trial training) are not eligible for inclusion.
• Tasks may be completed in pen-and-paper format or
through computerised exercises, or may be structured analogues
of everyday tasks in which the cognitive underpinnings are
explicit, and the intervention targets a cognitive ability or process
rather than a specific skill. The nature of the intervention (i.e.
computerised or pen-and-paper or analogues of daily activities)
will be noted.
• Interventions may be delivered on commercially-available
platforms, or be designed specifically for the purposes of the
study.
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• Interventions can target single or multiple cognitive
domains.
• Level of difficulty is expected to vary, however this will not
form part of the inclusion criteria.
• We will exclude from this review interventions in which
cognitive training was combined with another distinct
experimental intervention (e.g. physical activity, brain
stimulation), but this does not apply to standard treatments as
participants are generally expected to remain on their standard
(usually pharmacological) treatment.
• Modified/alternative cognitive training: it is acknowledged
that CT and other cognition-oriented treatment approaches (i.e.
cognitive stimulation or rehabilitation) may share some features,
and are not always straightforward to distinguish between.
Hence, we will include trials of complex cognition-oriented
treatments that also include elements of cognitive stimulation
(e.g. orientation), rehabilitation (e.g. goal setting), or
psychoeducation (e.g. using cognitive strategies) if it is
determined by consensus that CT is clearly the predominant
component. Where relevant and indicated by statistical
heterogeneity, we will consider these interventions separately in
subgroup analyses.
Comparator interventions
• Wait-list. In studies of this kind, the experimental
intervention is offered to the control group after the study had
ended.
• No treatment/standard treatment. Unless otherwise
specified, whenever groups are described as ’no treatment’ in
individual studies, we will assume that this refers to the usual/
standard treatment, and not to withholding of treatment. ’Usual
or standard treatment’ refers to what would normally be
provided in the study locality to participants with mild
dementia, and might include provision of medication, clinic
consultations, contact with a community mental health team,
day care or support from voluntary organisations, but not a
specific cognitive training intervention.
• Active control. This refers to conditions in which
participants engage in some form of activity, typically for an
equivalent number of sessions or visits, and receive similar levels
of contact with the researchers, but during which no structured
intervention is offered.
• Alternative treatment. These are distinct, alternative
treatments, either cognition-focused (e.g. cognitive stimulation),
or not (e.g. physical activity).
All interventions
• We will include interventions conducted in individual or
group format, with or without involvement of family caregivers.
• We will not impose restrictions regarding intervention
dose-related parameters, including the overall duration of the
intervention or the number of treatment sessions. However, as
described above, we will exclude single-session treatments.
Types of outcome measures
We considered outcomes within the following broad categories as
relevant for this review:
• clinical disease progression;
• cognitive outcomes;
• psychosocial outcomes for the person with dementia;
• psychosocial outcomes for the primary caregiver;
• surrogate/mechanism/biomarker outcomes;
• economic outcomes.
Although it is acknowledged that surrogate and economic out-
comes are important, we determined them to be beyond the scope
of the current review, and so the main primary and secondary
outcomes will be selected from the top four categories, as further
outlined below.
Primary outcomes
Outcomes for the person with dementia
• Global cognitive status at the end of treatment (i.e.
immediately post-intervention). We will measure this by change
in scores on screening measures of global cognition (e.g. MMSE,
Montreal Cognitive Assessment (MoCa), and Alzheimer’s
Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)).
• Clinical disease severity in the short to medium term. We
will measure this by change in scores on measures of clinical
disease progression (e.g. CDR, DRS) in a follow-up assessment
conducted between 3 and 12 months after treatment cessation.
Secondary outcomes
Outcomes for the person with dementia
• Global cognitive status in the short to medium term. We
will measure this by change in scores on screening measures of
global cognition (e.g. MMSE, MoCA, ADAS-Cog) at the
relevant follow-up assessment.
• Domain-specific cognitive status at the end of treatment.
We will measure this by change in scores on neuropsychological
measures of: global cognitive composite scores, speed of
processing, immediate memory, delayed memory, attention and
working memory, language (naming), verbal letter fluency, verbal
category fluency, and executive function.
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• Domain-specific cognitive status in the short to medium
term. We will measure this by change in scores on
neuropsychological measures of: global cognitive composite
scores, speed of processing, immediate memory, delayed memory,
attention and working memory, language (naming), verbal letter
fluency, verbal category fluency and executive function.
• Meta-cognition (self-reported) at the end of treatment, and
in the short to medium term.
• Meta-cognition (informant-reported) at the end of
treatment, and in the short to medium term.
• Mood (as reflected in change in self- or informant-reported
measures of depression, anxiety, etc.) at the end of treatment and
in the short to medium term.
• Capacity for activities of daily living, at the end of
treatment and in the short to medium term.
• Behavioural and psychological symptoms of dementia
(BPSD) at the end of treatment and in the short to medium term.
• General health or quality of life at the end of treatment and
in the short to medium term.
• Participant burden as reflected in rates of retention of trial
participants at the end of treatment.
Outcomes for the primary caregiver at the end of treatment
• Mood and well-being (as reflected in change in self reported
measures of depression, anxiety, etc.) at the end of treatment and
in the short to medium term)
• Burden of care at the end of treatment and in the short to
medium term.
• Quality of life at the end of treatment and in the short to
medium term.
Outcome measures
Where possible, we will use data from published and validated
tests, questionnaires or techniques for the evaluation of a given
outcome. In cases in which an outcome is evaluated by an unpub-
lished or non-established measure, we will make every effort to
source information about the statistical properties of the test or
scale in question, before determining whether or not to accept the
measure. We will classify the cognitive measures to specific cogni-
tive domains according to established authoritative texts (Spreen
1998), wherever possible, and by consensus between the study au-
thors as required.
Outcome evaluation
We will include trials if they include, at minimum, a baseline
evaluation, and one post-treatment evaluation.
Search methods for identification of studies
Electronic searches
We will search ALOIS (www.medicine.ox.ac.uk/alois), the
Cochrane Dementia and Cognitive Improvement Group’s (CD-
CIG) specialised register.
ALOIS is maintained by the Information Specialists for the
Cochrane Dementia and Cognitive Improvement Group, and
contains studies that fall within the areas of dementia prevention,
dementia treatment andmanagement, and cognitive enhancement
in healthy elderly populations. The studies are identified through:
1. searching a number of major healthcare databases:
MEDLINE, Embase, CINAHL and PsycINFO;
2. searching a number of trial registers: ClinicalTrials.gov and
the World Health Organization’s International Clinical Trials
Register Platform (ICTRP) which covers ISRCTN; the Chinese
Clinical Trials Register; the German Clinical Trials Register; the
Iranian Registry of Clinical Trials and the Netherlands National
Trials Register, plus others;
3. searching the Cochrane Library’s Central Register of
Controlled Trials (CENTRAL);
4. searching grey literature sources: ISI Web of Science Core
Collection.
To view a list of all sources searched for ALOIS, please visit the
ALOIS website ( www.medicine.ox.ac.uk/alois).
Details of the search strategies run in healthcare bibliographic
databases, used for the retrieval of reports of dementia, cognitive
improvement and cognitive enhancement trials, can be viewed
on the Cochrane Dementia and Cognitive Improvement Group’s
website: http://dementia.cochrane.org/searches
We will run additional searches in MEDLINE, Embase,
PsycINFO, Cinhal, LILACs, ClinicalTrials.gov and the WHO
Portal/ICTRP to ensure that the searches for this review are as
comprehensive and as up-to-date as possible. The search strategy
that will be used for the retrieval of reports of trials from MED-
LINE (via the Ovid SP platform) can be seen in Appendix 1.
Searching other resources
We will screen reference lists from included trials, as well as the
reference lists of recent systematic reviews, and relevant recent
guidelines.
We will contact experts in the field in order to obtain additional
randomised trial reports not identified by the search.
Data collection and analysis
Selection of studies
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One review author (AM) will review titles and abstracts from the
complete de-duplicated list of search results, and we will split the
records for an independent screening by two additional authors
(ABF, AG), in order to identify all potentially relevant RCTs of
cognitive training for people with dementia and to remove ob-
viously irrelevant studies. Whenever there is doubt regarding the
eligibility of a trial, we will select it for full review of the methods.
Following the initial screening, we will apply the same approach
for the evaluation of the full methods from shortlisted articles. We
will identify and merge multiple reports from the same study, and
contact study authors to clarify issues related to the eligibility of a
trial for inclusion. We will settle discrepancies in the classification
of trials through discussion between two review authors and ruling
of a senior author who is a content area expert (LC). The study
selection process will be unblinded.
Data extraction and management
A trained research assistant (JS) will extract data from study re-
ports onto a standardised, structured data entry form under the
supervision of the lead author (ABF), who will also independently
extract data for variables requiring some judgement (e.g. interven-
tion integrity/fidelity), and we will subsequently enter the data
into Review Manager 5 software (Review Manager 5). We will
seek additional information from study authors as appropriate.
Data extracted from each trial will include detailed characteristics
of the trials (e.g. settings, outcomes), design features (e.g. deliv-
ery format, blinding), participant characteristics (e.g. diagnoses,
age, gender, education, medications), elements of the experimen-
tal and control interventions (e.g. intensity, frequency, duration,
key intervention features). We will also extract information about
additional variables of interest for the investigation of effect mod-
erators, including registration status, sources of funding, conflict
of interest, adherence and retention, type of control, whether in-
tervention integrity/fidelity was addressed, and adverse events. For
each outcome of interest, we will extract mean scores and standard
deviations on relevant measures from all available evaluations.
Assessment of risk of bias in included studies
Pairs of review authors will independently conduct the assessment
of risk of bias using Cochrane’s ’Risk of bias’ tool (Higgins 2011).
We will resolve disagreements by discussion with a third reviewer
who is a subject matter expert (LC). Consistent with theCochrane
’Risk of bias’ tool, we will assess bias in the following domains:
sequence generation, allocation concealment, blinding of partic-
ipants and investigators, incomplete outcome data and selective
reporting of outcomes. We will rate studies as ’low risk’, ’high risk’
or ’unclear risk’ in each of these domains.
Measures of treatment effect
We will generally calculate effect estimates in primary trials along
with their 95%confidence intervals (CIs) using change-from-base-
line scores. Calculations of the standard deviation of change scores
will make the assumption that the correlation between measure-
ments at baseline and those at subsequent time points is r = 0.8, in
keeping with other relevant reviews (e.g. Lampit 2014). However,
for consistency with previous versions of this review, we will also
conduct sensitivity analyses of the primary outcome with a con-
servative r = 0 assumption which overestimates the standard devi-
ation of the change. We will treat outcome measures as measured
on a continuous scale. In some cases, outcomes will be derived
from ordinal rating scales; provided these contain a reasonably
large number of categories (more than 10), we will treat data as
continuous variables arising from a normal distribution. For di-
chotomous outcomes (e.g. participant retention), we will express
effects as the risk ratio (RR) along with 95% CIs.
Unit of analysis issues
We expect four types of unit of analysis issue: cross-over trial
designs, multiple-armed trials (more than one treatment/control
condition), repeated assessments, and the availability of multiple
measures of the same outcome in primary trials. Our approach to
the management of these issues will be as follows.
• Cross-over trials: we will only use data from the first
treatment period (before crossover).
• Multiple conditions
◦ Experimental conditions: in trials that include at least
three conditions, assuming that at least one condition satisfies
our definition of a comparison condition (see above), we will
combine data from all conditions that are judged to fit our
definition of CT into a single group using relevant formula
(Higgins 2011). We will exclude from this review trials that
include two relevant experimental conditions but no eligible
control condition.
◦ Control conditions: we will combine data from two
control conditions of the same broad type (i.e. no treatment). In
the event that a trial includes different types of control
comparisons which are not alternative treatments (e.g. it includes
both no treatment and active control groups), we will use in the
analysis data from both these control conditions by splitting the
sample size of the experimental condition into two separate
groups, following the procedure described in Chapter 7 of the
Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
• Repeated post-intervention assessments: we will conduct
separate comparisons to assess the primary and secondary
outcomes at the end of treatment (i.e. immediately post-
intervention), and in the short to medium term (up to 12
months post-intervention). Within this follow-up period, we will
use in the analysis data from the last available assessment We will
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not use data from follow-up assessments conducted more than
12 months following the end of treatment assessment.
• Multiple measures of the same outcome: in primary trials in
which multiple measures of the same outcome are used, the
following principles will guide the selection of measures for data
extraction.
◦ General principles: we will use a composite outcome
measure if one was derived by the authors. If no composite is
available, we will generally use data from a test that matches the
most commonly used measure in other studies that contributed
data to the particular outcome. Established/published measures
of the outcome will be preferred over measures developed for the
specific study. If more than one established measure of an
outcome was used, and no measure is identified that was used by
the majority of trials contributing to the specific outcome, we
will create a simple composite score from the standardised scores
on the different measures and use it in the analysis.
◦ Cognitive outcomes: for each trial, we will compute a
global composite cognitive score by calculating a standardised
change-from-baseline score from each measure (change score
divided by the standard deviation of the change score), and
deriving a simple mean and standard deviation of the Z scores
associated with all cognitive measures from a trial. In addition,
for the evaluation of domain-specific cognitive scores, we will use
the following principles:
⋄ Psychomotor information processing speed. We
will prefer visuospatial measures where available
⋄ Attention, immediate and delayed memory. We
will prefer auditory-verbal measures for the evaluation of
attention, immediate and delayed memory. We will prefer tasks
that involve the learning of information over several trials (i.e.
word lists) over tasks in which the information is only presented
once (e.g. story or figure recall). We will prefer measures of free
recall over measures of cued/recognition where available.
⋄ Executive functions. We will prefer tasks that
reflect planning, organisation, decision-making, regulation of
performance and set-shifting aspects of executive functions over
tasks that are more strongly associated with volition or purposive
action aspects of executive functions (Lezak 2004). In the event
that several measures of executive function were used in a study,
we will compute a composite executive function score by taking
the mean of the standardised scores for each of these measures.
◦ For meta cognitive outcomes, we will generally prefer
self-reported measures of contentment/satisfaction with one’s
cognitive ability over informant-reported measures.
◦ Mood outcomes: we will generally prefer measures of
depression over measures of anxiety or apathy, and self-reported
measures over informant-reported measures.
◦ Activities of daily living (ADL): we will prefer
measures of instrumental ADLs over measures of basic ADLs,
and informant-reported measures over self-reported measures.
This is based on the finding that self- and informant-reported
daily function show significant discrepancy in people with
dementia, and that informant reports of daily function are more
closely associated with actual memory performance (Farias
2005).
Dealing with missing data
We will extract the number of participants who commenced and
completed the intervention in each condition, and this will con-
tribute to the assessment of risk of bias due to incomplete outcome
data. Wherever possible, we will contact trial authors in an effort
to obtain relevant unreported data. In general, we will assume that
data are missing at random, and analyses in individual studies are
generally performed on a per protocol (PP) rather than on an in-
tention-to-treat basis (ITT). When a trial report includes relevant
data from both the ITT and PP samples, we will generally use the
PP data for consistency with most of the trials. We will evaluate
the impact of missing data on pooled effect estimates in sensitivity
analyses (see below).
Assessment of heterogeneity
In addition to a visual inspection of the forest plots, we will assess
statistical heterogeneity using a standard Chi2 statistic and the
associated l2 statistic. Consistent with recommendations (Deeks
2017), we will deem heterogeneity to be present when the Chi2
statistic is significant at the P = 0.1 level, or when the l2 suggests
that more than 40% of the variability in effect estimate is due to
heterogeneity.Where substantial heterogeneity is detected, we will
explore the sources of heterogeneity through subgroup analyses
(see below).
Assessment of reporting biases
For the primary outcomes, we will first evaluate the presence of
reporting bias through a visual examination of funnel plots for
small study effects. We will examine the significance of any ap-
parent asymmetry with Egger’s Test (Egger 1997), and follow up
with the ’trim and fill’ test (Duval 2000), if asymmetry of the plot
is confirmed.
Data synthesis
We will perform data synthesis using Review Manager 5 software.
In relation to each of the main outcomes of interest, we plan to
undertake the following separate comparisons.
1. Cognitive training versus control (no/standard treatment/
wait list or active control) at the end of the treatment (i.e.
immediately post-intervention).
2. Cognitive training versus control (no/standard treatment/
wait list or active control) in the short to medium term (3 to 12
months following end of treatment).
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3. Cognitive training versus alternative treatment at the end of
the treatment (i.e. immediately post-intervention).
4. Cognitive training versus alternative treatment in the short
to medium term (3 to 12 months following end of treatment).
Within each of the planned comparisons, we will pool data in
relation to each outcome of interest when data from at least two
trials are available.
We will perform inverse-variance, random-effects meta-analyses
for all outcomes. We will use the mean difference (MD) with 95%
CIs whenever studies used the same outcome measure, whereas
we will use the standardised mean difference (SMD), which is the
absolutemeandifference divided by the pooled standard deviation,
when the same outcome is assessed by different measures.
In relation to the primary outcomes, we will express the overall
quality and confidence in the evidence using GRADE levels and
present this in ’Summary of findings’ tables.
GRADE and ’Summary of findings’ tables
We will describe the quality of evidence as ’high’, ’moderate’, ’low’
or ’very low’, using the GRADE framework, which we will apply
to all primary and secondary outcomes in each of the comparisons.
We will generate ’Summary of findings’ tables using GRADEpro
GDT software (GRADEpro GDT) and import these into the
review. The ’Summary of findings’ tables will include the following
primary and secondary outcomes.
• Global cognition at the end of the intervention
• Clinical disease severity at the latest follow-up, up to 12
months following treatment cessation
• Delayed memory ability at the end of the intervention
• Capacity to perform activities of daily living
• Mood and well-being (participant)
• Mood and well-being (informant/caregiver)
• Treatment burden (retention rates)
Subgroup analysis and investigation of heterogeneity
In relation to each outcome, we will carry out subgroup analyses to
evaluate the potential impact of categorical treatment modifiers.
We will only carry out subgroup analyses where statistical hetero-
geneity is suggested by the relevant statistics (I2 of 40% or more)
(Deeks 2017), and assuming that at least three studies are avail-
able for each subgroup. We will examine the following categorical
effect modifiers.
• Type of intervention 1: CT versus CT combined with
elements of cognitive rehabilitation or cognitive stimulation (or
both).
• Type of intervention 2: multidomain CT versus single
domain (e.g. working memory).
• Intervention dose: more intense (i.e. more than three
formal sessions per week) versus less intense interventions (i.e. up
to three formal sessions per week).
• Intervention duration: longer interventions (i.e. more than
three months) versus shorter interventions (i.e. three months or
less).
• Follow-up period: we will compare studies with follow-up
in the short term (up to three months after treatment cessation)
with trials that included longer term follow-up (up to 12 months
after treatment cessation).
• Risk of bias: studies with high risk of bias in at least two
critical domains versus other studies with lower risk of bias. For
the purposes of these analyses, critical domains are sequence
generation, blinding of outcome assessment, incomplete data,
and selective reporting. Although we acknowledge that allocation
concealment is also increasingly regarded as a critical domain,
this remains a relatively infrequent practice in these types of
studies.
• Funding source: trials funded by commercial entities versus
those based on competitive funding.
• Registration: registration status of the trial (prospective,
retrospective, not-registered/not reported).
Sensitivity analysis
To determine whether findings for the primary outcomes are af-
fected by assumptions made regarding the strength of the corre-
lation between scores before and following the interventions, we
will repeat the analyses of the primary outcomes after applying
the zero correlation assumption, which overestimates the standard
deviation of change scores. We will repeat the evaluation of the
primary outcomes by a further sensitivity analysis using post-in-
tervention scores only, thus avoiding the need to estimate the stan-
dard deviation of change scores.
A C K N OW L E D G E M E N T S
For the current version
For previous versions:
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1 exp Dementia/
2 Delirium, Dementia, Amnestic, Cognitive Disorders/
3 dement*.mp.
4 alzheimer*.mp.
5 (lewy* adj2 bod*).mp.
6 (chronic adj2 cerebrovascular).mp.
7 (“organic brain disease” or “organic brain syndrome”).mp.
8 (cerebr* adj2 deteriorat*).mp.
9 (cerebral* adj2 insufficient*).mp.
10 (pick* adj2 disease).mp.
11 PDD.mp.
12 “Parkinson* disease dementia”.mp.
13 or/1-12
14 *Cognitive Therapy/
15 Rehabilitation Nursing/
16 Cognitive Remediation/
17 (cognit* adj2 stimulation).ti,ab.
18 (cognit* adj2 rehabilitation).ti,ab.
19 (cognit* adj2 training).ti,ab.
20 (cognit* adj2 retrain*).ti,ab.
21 “cognitive intervention*”.ti,ab.
22 “Cognitive skills ADJ2 training”.ti,ab.
23 “cognitive support”.ti,ab.
24 “Cog* retrain*”.ti,ab.
25 “memory function*”.ti,ab.
26 (memory adj2 rehabilitation).ti,ab.
27 (memory adj2 therap*).ti,ab.
28 “memory aid*”.ti,ab.
29 “memory group*”.ti,ab.
30 “Memory rehabilitation”.ti,ab.
31 “memory training”.ti,ab.
32 “memory retraining”.ti,ab.
33 “Memory rehabilitation”.ti,ab.
34 “memory re-training”.ti,ab.
35 “memory support”.ti,ab.
36 “memory stimulation”.ti,ab.
37 “memory strateg*”.ti,ab.
38 “memory management”.ti,ab.
39 or/14-38
40 randomized controlled trial.pt.
41 controlled clinical trial.pt.
42 randomized.ab.
43 placebo.ab.
44 randomly.ab.
45 trial.ab.
46 groups.ab.
47 or/40-46
48 (animals not (humans and animals)).sh.
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49 47 not 48
50 13 and 39 and 49
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